Advertisement
U.S. markets closed

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
29.51-1.12 (-3.66%)
At close: 04:00PM EDT
29.51 0.00 (0.00%)
After hours: 04:05PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close30.63
Open30.50
Bid29.48 x 100
Ask29.57 x 200
Day's Range28.71 - 30.69
52 Week Range19.80 - 35.50
Volume680,794
Avg. Volume816,183
Market Cap1.658B
Beta (5Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)-6.33
Earnings DateMay 02, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AGIO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Agios Pharmaceuticals, Inc.
    JAZZ: Lowering target price to $120.00JAZZ PHARMACEUTICALS PLC has an Investment Rating of HOLD; a target price of $120.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GuruFocus.com

    Director Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO)

    Agios Pharmaceuticals Inc (NASDAQ:AGIO), a biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of cancer and rare genetic diseases, has seen a recent insider transaction according to the latest SEC filings.

  • GlobeNewswire

    Agios Publishes 2024 Environmental, Social and Governance (ESG) Report

    – Report Highlights Company’s Focus on Red Blood Cell Health; Diversity, Equity & Inclusion; and Strong Corporate Governance – – Aligns with the Sustainability Accounting Standards Board (SASB) Standards for the Biotechnology and Pharmaceuticals Industry and the United Nations Sustainable Development Goals (UN SDGs) – CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare dis

  • Simply Wall St.

    We Think Agios Pharmaceuticals (NASDAQ:AGIO) Can Afford To Drive Business Growth

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...